Antitumor agent-88 exhibits potent antimitotic activity and induces cell cycle arrest at the G2/M phase; it disrupts microtubules and the cytoskeleton in CYP1A1-expressing breast cancer cells; it also acts as a competitive inhibitor of CYP1A1 (Ki: 1.4 μM).